Cargando…
Synapsin II Is Involved in the Molecular Pathway of Lithium Treatment in Bipolar Disorder
Bipolar disorder (BD) is a debilitating psychiatric condition with a prevalence of 1–2% in the general population that is characterized by severe episodic shifts in mood ranging from depressive to manic episodes. One of the most common treatments is lithium (Li), with successful response in 30–60% o...
Autores principales: | Cruceanu, Cristiana, Alda, Martin, Grof, Paul, Rouleau, Guy A., Turecki, Gustavo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286475/ https://www.ncbi.nlm.nih.gov/pubmed/22384280 http://dx.doi.org/10.1371/journal.pone.0032680 |
Ejemplares similares
-
DNA hypomethylation of Synapsin II CpG islands associates with increased gene expression in bipolar disorder and major depression
por: Cruceanu, Cristiana, et al.
Publicado: (2016) -
Lithium: a key to the genetics of bipolar disorder
por: Cruceanu, Cristiana, et al.
Publicado: (2009) -
No association between the PREP gene and lithium responsive bipolar disorder
por: Mamdani, Firoza, et al.
Publicado: (2007) -
Novel integrative genomic tool for interrogating lithium response in bipolar disorder
por: Hunsberger, J G, et al.
Publicado: (2015) -
Exemplar scoring identifies genetically separable phenotypes of lithium responsive bipolar disorder
por: Nunes, Abraham, et al.
Publicado: (2021)